IBM Watson Health, Aetion partner to advance biopharma research

IBM Watson Health and Aetion codeveloped a tool enabling small and mid-size biopharmaceutical companies to conduct advanced data analysis of real-world evidence to evaluate the safety and effectiveness of new medical treatments.

The solution integrates medical and drug claims data from the IBM MarketScan research databases into Aetion's Evidence Platform. Biopharma companies can now use the platform to analyze claims data to find answers to questions about the safety, medical affairs and market access of the treatments they develop.

Available analyses include feasibility counts, prevalence and incidence, disease burden, population exploration, drug treatment pathways, hypothesis generation, comparative safety and comparative effectiveness.

"Historically, substantial investment in real-world evidence has been almost the exclusive domain of large pharma," Carolyn Magill, Aetion CEO, said in a news release. "By combining IBM Watson Health's data source and a best-in-class analytics platform in this bundled offering, innovative midmarket biopharma companies can now benefit from integrating real-world data into drug development and commercialization to help them solve data-driven challenges."

More articles on health IT:
University Hospitals receives $15M for men's healthcare innovation
Washington University School of Medicine notifies patients of data breach
Google developing enhanced search functions for EHRs

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.